MG-ADL: Still a relevant outcome measure

Muscle and Nerve

Volumn 44, Issue 5, 2011, Pages 727-731

  Muppidi, Srikanth ^a   Wolfe, Gil I ^a   Conaway, Mark ^b   Burns, Ted M ^c  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b UNIVERSITY OF VIRGINIA   (United States)

^c UNIVERSITY OF VIRGINIA   (United States)

Author keywords

MG outcome measures; MG scales; MG ADL; MGC and mGQOl15; Myasthenia gravis

Indexed keywords

ADULT; ARTICLE; CLINICAL ASSESSMENT TOOL; CONTROLLED STUDY; CORRELATION COEFFICIENT; DAILY LIFE ACTIVITY; DESCRIPTIVE RESEARCH; DIAGNOSTIC TEST ACCURACY STUDY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MYASTHENIA GRAVIS; MYASTHENIA GRAVIS SPECIFIC ACTIVITIES OF DAILY LIVING SCALE; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; QUALITY OF LIFE; RATING SCALE; RECEIVER OPERATING CHARACTERISTIC; SCORING SYSTEM; SENSITIVITY AND SPECIFICITY; TEST RETEST RELIABILITY; VALIDATION STUDY;

ACTIVITIES OF DAILY LIVING; FEMALE; HUMANS; MALE; MIDDLE AGED; MYASTHENIA GRAVIS; OUTCOME ASSESSMENT (HEALTH CARE); QUESTIONNAIRES; REPRODUCIBILITY OF RESULTS;

EID: 80054850011     PISSN: 0148639X     EISSN: 10974598     Source Type: Journal    
DOI: 10.1002/mus.22140     Document Type: Article

References (17)

1. Burns TM. History of outcome measures for myasthenia gravis. Muscle Nerve 2010;42:5-13.
2. Barohn RJ. Standards of measurements in myasthenia gravis. Ann NY Acad Sci 2003;998:432-439.
3. Burns TM, Conaway M, Sanders DB. The MG Composite: a valid and reliable outcome measure for myasthenia gravis. Neurology 2010;74: 1434-1440.
4. Burns TM, Conaway MR, Cutter GR, Sanders DB. Construction of an efficient evaluative instrument for myasthenia gravis: the MG composite. Muscle Nerve 2008;38:1553-1562.
5. Burns TM, Conaway MR, Cutter GR, Sanders DB. Less is more, or almost as much: a 15-item quality-of-life instrument for myasthenia gravis. Muscle Nerve 2008;38:957-963.
6. Farrugia ME, Robson MD, Clover L, Anslow P, Newsom-Davis J, Kennett R, et al. MRI and clinical studies of facial and bulbar muscle involvement in MuSK antibody-associated myasthenia gravis. Brain 2006;129:1481-1492.
7. Gajdos P, Sharshar T, Chevret S. Standards of measurements in myasthenia gravis. Ann NY Acad Sci 2003;998:445-452.
8. Mantegazza R, Antozzi C, Peluchetti D, Sghirlanzoni A, Cornelio F. Azathioprine as a single drug or in combination with steroids in the treatment of myasthenia gravis. J Neurol 1988;235:449-453.
9. Padua L, Evoli A, Aprile I, Caliandro P, Batocchi AP, Punzi C, et al. Myasthenia gravis outcome measure: development and validation of a disease-specific self-administered questionnaire. Neurol Sci 2002; 23:59-68.
10. Sanders DB, Tucker-Lipscomb B, Massey JM. A simple manual muscle test for myasthenia gravis: validation and comparison with the QMG score. Ann NY Acad Sci 2003;998:440-444.
11. Wolfe GI, Herbelin L, Nations SP, Foster B, Bryan WW, Barohn RJ. Myasthenia gravis activities of daily living profile. Neurology 1999;52: 1487-1489.
12. Barohn RJ, McIntire D, Herbelin L, Wolfe GI, Nations S, Bryan WW. Reliability testing of the quantitative myasthenia gravis score. Ann NY Acad Sci 1998;841:769-772.
13. Muscle Study Group.A trial of mycophenolate mofetil with prednisone as initial immunotherapy in myasthenia gravis. Neurology 2008; 71:394-399.
14. Wolfe GI, Barohn RJ, Sanders DB, McDermott MP. Comparison of outcome measures from a trial of mycophenolate mofetil in myasthenia gravis. Muscle Nerve 2008;38:1429-1433.
15. Mantegazza R, Beghi E, Pareyson D, Antozzi C, Peluchetti D, Sghirlanzoni A, Cosi V, et al. A multicentre follow-up study of 1152 patients with myasthenia gravis in Italy. J Neurol 1990;237:339-344.
16. Grob D, Brunner N, Namba T, Pagala M. Lifetime course of myasthenia gravis. Muscle Nerve 2008;37:141-149.
17. Oosterhuis HJ. Studies in myasthenia gravis. 1. A clinical study of 180 patients. J Neurol Sci 1964;38:512-546.